JLGutierrez
The U.S. Patent and Trademark Workplace (USPTO) has invalidated all claims made by Pfizer’s (NYSE:PFE) current buyout, Seagen (SGEN), relating to a patent associated to Enhertu, a most cancers remedy marketed by Daiichi Sankyo (OTCPK:DSKYF) with AstraZeneca (NASDAQ:AZN).
In a press launch on Wednesday, the Japanese drug maker stated that the USPTO issued a remaining written resolution invalidating all claims associated to Seagen’s U.S. patent 10,808,039 (the ’039 patent) in response to a petition filed for a post-grant overview.
“We’re happy that the U.S. PTO invalidated all challenged claims of the ’039 patent,” Daiichi’s (OTCPK:DSNKY) Normal Counsel, Naoto Tsukaguchi, remarked.
The dispute can also be the topic of a number of courtroom proceedings. In 2022, a jury in a U.S. District Courtroom in Texas discovered that Daiichi infringed the ‘039 patent with Enhertu.
A federal choose in the identical courthouse agreed in a subsequent judgment, over which an attraction is at present pending within the U.S. Courtroom of Appeals for the Federal Circuit.